Advertisement

Symptom-Triggered Therapy for Alcohol Withdrawal Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials

  • Jürgen L. HolleckEmail author
  • Naseema Merchant
  • Craig G. Gunderson
Review Paper
  • 109 Downloads

Abstract

Background

Benzodiazepines are the standard medication class for treating alcohol withdrawal. Guidelines recommend dosing based on objectively measured symptoms (symptom-triggered therapy) rather than fixed dose regimens. However, the superiority of symptom-triggered therapy has been questioned, and concerns have been raised about its inappropriate use and safety. We aimed to assess whether symptom-triggered therapy is superior to fixed dose schedules in terms of mortality, delirium, seizures, total benzodiazepine dose, and duration of therapy.

Methods

A systematic literature search using Medline, Embase, and the Cochrane Registry through February 2018 was conducted for randomized controlled trials of patients with alcohol withdrawal syndrome comparing fixed dose benzodiazepine schedules to symptom-triggered therapy. Risk of bias was assessed using the Cochrane Risk of Bias Tool. Outcomes were pooled using random effects meta-analysis. Heterogeneity was estimated using the I2 statistic. Strength of evidence was assessed using methods outlined by the Agency for Healthcare Research and Quality.

Results

Six studies involving 664 patients were included. There were no deaths and only one seizure in each group. Four studies reported delirium, which occurred in 4 out of 164 patients randomized to symptom-triggered therapy compared to 6 out of 164 randomized to fixed dose therapy (odds ratio, 0.64 [95% CI, 0.17–2.47]). Three studies reported duration of therapy, which was 60.4 h less with symptom-triggered therapy (95% CI, 39.7–81.1 h; p < 0.001). Six studies reported total benzodiazepine dosage, which was 10.5 mg in lorazepam-equivalent dosing less with symptom-triggered therapy (95% CI, 7.1–13.9 mg; p = 0.011).

Discussion

Moderate strength evidence suggests that symptom-triggered therapy improved duration of therapy and total benzodiazepine dose in specialized detoxification settings of low-risk patients but the applicability of this evidence in general hospital settings is low. There was insufficient evidence for any conclusions about symptom-triggered therapy for the major outcomes of mortality, seizure, and delirium in any setting.

PROSPERO Registration

CRD42017073426

KEY WORDS

alcohol withdrawal delirium benzodiazepines evidence-based medicine meta-analysis 

Notes

Acknowledgements

The authors would like to thank reference librarians Jessica Patterson and Jennifer Martin at VACT and Minna Holleck for her Spanish translation.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they do not have a conflict of interest.

References

  1. 1.
    Grant BF, Goldstein RB, Saha TD, et al. Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015;72(8):757–766.CrossRefGoogle Scholar
  2. 2.
    Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. JAMA. 1989;261(3):403–407.CrossRefGoogle Scholar
  3. 3.
    Schuckit MA. Recognition and management of withdrawal delirium (delirium tremens). N Engl J Med. 2014;371(22):2109–2113.CrossRefGoogle Scholar
  4. 4.
    Mayo-Smith MF, Beecher LH, Fischer TL, et al. Management of alcohol withdrawal delirium. An evidence-based practice guideline. Arch Intern Med. 2004;164(13):1405–1412.CrossRefGoogle Scholar
  5. 5.
    O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med. 1998;338(9):592–602.CrossRefGoogle Scholar
  6. 6.
    Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278(2):144–151.CrossRefGoogle Scholar
  7. 7.
    Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348(18):1786–1795.CrossRefGoogle Scholar
  8. 8.
    Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict. 1989;84(11):1353–1357.CrossRefGoogle Scholar
  9. 9.
    Maldonado JR, Nguyen LH, Schader EM, Brooks JO 3rd. Benzodiazepine loading versus symptom-triggered treatment of alcohol withdrawal: a prospective, randomized clinical trial. Gen Hosp Psychiatry. 2012;34(6):611–617.CrossRefGoogle Scholar
  10. 10.
    Hecksel KA, Bostwick JM, Jaeger TM, Cha SS. Inappropriate use of symptom-triggered therapy for alcohol withdrawal in the general hospital. Mayo Clin Proc. 2008;83(3):274–279.CrossRefGoogle Scholar
  11. 11.
    Pletcher MJ, Fernandez A, May TA, et al. Unintended consequences of a quality improvement program designed to improve treatment of alcohol withdrawal in hospitalized patients. Jt Comm J Qual Patient Saf. 2005;31(3):148–157.CrossRefGoogle Scholar
  12. 12.
    Finn KM, Greenwald J. Hospitalists and alcohol withdrawal: yes, give benzodiazepines but is that the whole story? J Hosp Med. 2011;6(8):435–437.CrossRefGoogle Scholar
  13. 13.
    Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.CrossRefGoogle Scholar
  14. 14.
    Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.CrossRefGoogle Scholar
  15. 15.
    Berkman ND, Lohr KN, Ansari M, et al. Grading the Strength of a Body of Evidence When Assessing Health Care Interventions for the Effective Health Care Program of the Agency for Healthcare Research and Quality: An Update. Methods Guide for Comparative Effectiveness Reviews (Prepared by the RTI-UNC Evidence-based Practice Center under Contract No. 290-2007-10056-I). AHRQ Publication No. 13(14)-EHC130-EF. Rockville, MD: Agency for Healthcare Research and Quality. November 2013. www.effectivehealthcare.ahrq.gov/reports/final.cfm.
  16. 16.
    Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res. 2018;27(6):1785–1805.CrossRefGoogle Scholar
  17. 17.
    Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135.CrossRefGoogle Scholar
  18. 18.
    Turner RC, Lichstein PR, Peden JG, Jr., Busher JT, Waivers LE. Alcohol withdrawal syndromes: a review of pathophysiology, clinical presentation, and treatment. J Gen Intern Med. 1989;4(5):432–444.CrossRefGoogle Scholar
  19. 19.
    Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR. Individualized treatment for alcohol withdrawal. A randomized double-blind controlled trial. JAMA. 1994;272(7):519–523.CrossRefGoogle Scholar
  20. 20.
    Weaver MF, Hoffman HJ, Johnson RE, Mauck K. Alcohol withdrawal pharmacotherapy for inpatients with medical comorbidity. J Addict Dis. 2006;25(2):17–24.CrossRefGoogle Scholar
  21. 21.
    Daeppen JB, Gache P, Landry U, et al. Symptom-triggered vs fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med. 2002;162(10):1117–1121.CrossRefGoogle Scholar
  22. 22.
    Elholm B, Larsen K, Hornnes N, Zierau F, Becker U. Alcohol withdrawal syndrome: symptom-triggered versus fixed-schedule treatment in an outpatient setting. Alcohol Alcohol. 2011;46(3):318–323.CrossRefGoogle Scholar
  23. 23.
    Sachdeva A, Chandra M, Deshpande SN. A comparative study of fixed tapering dose regimen versus symptom-triggered regimen of lorazepam for alcohol detoxification. Alcohol Alcohol. 2014;49(3):287–291.CrossRefGoogle Scholar

Copyright information

© Society of General Internal Medicine (This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply) 2019

Authors and Affiliations

  • Jürgen L. Holleck
    • 1
    • 2
    Email author
  • Naseema Merchant
    • 1
    • 2
  • Craig G. Gunderson
    • 1
    • 2
  1. 1.Department of Internal MedicineYale University School of MedicineNew HavenUSA
  2. 2.Department of Medicine, West Haven VA HospitalVeterans Affairs Connecticut Healthcare SystemWest HavenUSA

Personalised recommendations